Ligand Pharmaceuticals (LGND) Accumulated Expenses (2010 - 2026)

Ligand Pharmaceuticals (LGND) has 17 years of Accumulated Expenses data on file, last reported at $31.8 million in Q1 2026.

• For the quarter ending Q1 2026, Accumulated Expenses rose 35.3% year-over-year to $31.8 million; the trailing twelve-month figure through Mar 2026 stood at $31.8 million (up 35.3% YoY), and the FY2025 full-year result was $31.5 million, up 12.71% from the prior year.
• Accumulated Expenses advanced to $31.8 million in Q1 2026, from $31.5 million in the prior quarter.
• In the past five years, Accumulated Expenses ranged from a high of $31.8 million in Q1 2026 to a low of $7.3 million in Q2 2023.
• A 5-year average of $18.1 million and a median of $15.7 million in 2022 frame the typical range for Accumulated Expenses.
• Across the five-year window, Accumulated Expenses sank 49.89% in 2023 and soared 123.84% in 2024, its largest moves.
• Tracing LGND's Accumulated Expenses over 5 years: stood at $15.7 million in 2022, then decreased by 20.5% to $12.5 million in 2023, then surged by 123.84% to $27.9 million in 2024, then gained by 12.71% to $31.5 million in 2025, then grew by 1.25% to $31.8 million in 2026.
• Business Quant data shows LGND's Accumulated Expenses at $31.8 million in Q1 2026, $31.5 million in Q4 2025, and $24.1 million in Q3 2025.